Ratings Mesoblast Limited Nasdaq

Equities

MESO

US5907174016

Market Closed - Nasdaq Other stock markets 01:30:00 10/05/2024 am IST			5-day change	1st Jan Change
7.17 ^USD	-5.53%		-1.65%	+225.91%

01/04	ADRs End Higher; Connect Biopharma Climbs 26%	DJ
28/03	ADRs End Lower; NuCana Slides 15%	DJ

Summary

Overall, the company has poor fundamentals for a medium to long-term investment strategy.
From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

The prospective high growth for the next fiscal years is among the main assets of the company
Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.

Weaknesses

The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
The company has insufficient levels of profitability.
One of the major weak points of the company is its financial situation.
The company's "enterprise value to sales" ratio is among the highest in the world.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
For the past year, analysts have significantly revised downwards their profit estimates.
The average consensus view of analysts covering the stock has deteriorated over the past four months.
Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
MESOBLAST LIMITED	+225.91%	848M	-
MODERNA, INC.	+23.37%	46.71B	B-
LONZA GROUP AG	+48.83%	41.8B	A
IQVIA HOLDINGS INC.	-0.94%	41.52B	B
CELLTRION, INC.	-5.86%	29.55B	C
ICON PUBLIC LIMITED COMPANY	+11.29%	25.78B	B-
ALNYLAM PHARMACEUTICALS, INC.	-20.92%	19.26B	B
BIO-TECHNE CORPORATION	+3.20%	12.14B	B+
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-2.67%	12.08B	C+
MEDPACE HOLDINGS, INC.	+30.23%	11.98B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes